# FLGR242

> A supplier name for a claimed albumin-binding follistatin construct — not a molecule with a published sequence, structure, or study under this name.

- Also known as: FLGR-242
- Class: Growth Hormone, Metabolic
- FDA approved: No
- Canonical page: https://americanpeptide.com/catalog/flgr242

## Overview

FLGR242 is a catalog designation used by research-chemical suppliers, not an international nonproprietary name and not a molecule indexed in the peer-reviewed literature. The supplier that introduced it describes a fragmented, modified form of follistatin-344 fused through a glycine–serine linker to an albumin-binding peptide, states a mass of about 40 kDa, and states that the construct does not bind activin. Those are vendor claims. PubMed, under the names FLGR242 and FLGR-242, has no characterization of the material in the vial. The biology it is sold against is the follistatin–myostatin literature, which is a different body of evidence.

Follistatin is a real secreted glycoprotein (see the follistatin monograph). It binds myostatin and activin and, by taking both ligands out of circulation, disinhibits muscle growth. The credible human and primate data for that idea come from follistatin gene therapy (an FS-344 expression cassette), not from an injected modified protein. Isoforms matter: FS-315, the circulating form, binds activin about tenfold more weakly than the cell-surface form FS-288, which is one reason the gene-therapy constructs were built the way they were.

FLGR242 is the supplier’s name for what they say is a cut-down FST-344 fused to an albumin-binding sequence. One product specification states the linker-plus-binder as GGSGGSGGSGGRLIEDICLPRWGCLWEDD, a mass near 40 kDa, albumin affinity tighter than 20 nM, and a circulating half-life of about 19 days — the half-life of albumin itself. Each of those figures is a claim on a product page. No pharmacokinetic paper, no binding paper, and no muscle study uses the name. Predicting a fused protein’s human half-life from an albumin-binding tag is an open problem even for constructs that have been published.

The marketing context is lean mass during GLP-1 weight loss, the same conversation as myostatin antibodies and follistatin. That clinical question is real. A named construct with no public sequence confirmation, no independent binding data, and no animal or human study is not yet part of the answer. Long-acting blockade of this axis also has a published downside that belongs in the same paragraph: turning off myostatin signaling in the adult mouse heart caused hypertrophy and heart failure, and follistatin suppresses FSH. Those findings are about the pathway, not a demonstration that this vial does or does not do those things.

## Mechanism

The claimed mechanism is the follistatin mechanism: sequestration of myostatin away from ActRII receptors so Smad2/3 no longer brakes muscle growth, with the additional claims that activin binding has been removed and that an albumin-binding tag extends circulation. None of that selectivity or pharmacokinetics has been published for a molecule called FLGR242. Follistatin itself binds myostatin and activin; separating those two is a real protein-engineering problem, and it has not been shown in print for this designation.

## Chemistry

| Property | Value |
| --- | --- |
| Molecular weight | 40000 Da |

## Research areas

Studied in: Muscle growth, Myostatin, GLP-1 muscle preservation, Body composition.

Guides on this site:

- [Growth Hormone & Body Composition](https://americanpeptide.com/research-areas/growth-hormone-axis): Secretagogues studied for GH release, IGF-1, and body composition.
- [Muscle Preservation & Lean Mass](https://americanpeptide.com/research-areas/muscle-lean-mass): The activin/myostatin axis studied to preserve muscle during GLP-1 weight loss.

## Key research

- No paper under this name — searches of the literature return nothing that characterizes FLGR242. Sequence, selectivity, half-life, and muscle effects are supplier statements.
- What is claimed — a modified fragment of follistatin-344, an albumin-binding fusion stated as GGSGGSGGSGGRLIEDICLPRWGCLWEDD, about 40 kDa, and a claim of lost activin binding. Treat the linker as a stated formula, not a verified one.
- The evidence that does exist is about follistatin gene therapy and about myostatin-pathway antibodies, not about this protein. See follistatin, myostatin, and the activin-axis antibodies.
- Selectivity is the hard part — native follistatin binds myostatin and activin (and can touch GDF11 and BMPs). A claim that a fragment has dropped activin binding needs a published binding panel.
- Pathway cautions from other models — cardiac myostatin loss and FSH suppression are published properties of this axis, which is why a long-acting version would need its own safety data.

## Storage, handling & synthesis

**Storage.** Handled as a lyophilized recombinant protein: frozen, dry, and protected from light. The stated mass and fusion architecture are supplier figures, so storage follows the lot’s own certificate rather than a pharmacopeial monograph.

**Handling.** Treat as a glycosylated or fusion protein that can aggregate with heat, agitation, and freeze–thaw. A certificate of analysis for this designation should be read against the follistatin isoforms: mass near 40 kDa does not by itself identify the construct, the linker, or which ligands it still binds.

**Synthesis.** There is no published preparation. Suppliers describe a recombinant fusion — a fragment of follistatin-344 joined by a glycine–serine linker to an albumin-binding peptide — rather than a solid-phase peptide. Follistatin is a glycoprotein, so a genuine analogue of it is made in eukaryotic cells, and the mass depends on the fragment boundaries and on glycosylation. The linker sequence and the ~40 kDa figure circulate on product pages only. Identity work for a lot is mass spectrometry against a disclosed construct, plus a ligand-binding panel, neither of which is in the public record under this name.

## FAQs

### What is FLGR242?

A supplier designation for a protein sold as a modified, albumin-binding follistatin. It is not an INN, and no peer-reviewed paper describes a molecule by this name. The stated identity is a fragmented FST-344 fused to an albumin-binding peptide, at about 40 kDa.

### Is FLGR242 the same as follistatin-344?

Not as labeled. Follistatin-344 is a known isoform of the FST gene. FLGR242 is claimed to be a fragment of that isoform plus an albumin-binding tag, with activin binding removed. Until a sequence and a binding study are published, the vial and the gene product should not be treated as the same substance.

### Does it spare muscle during GLP-1 treatment?

There is no published animal or human study of FLGR242. Muscle preservation on incretin drugs is a real research question; the data on it come from other interventions, including myostatin-pathway antibodies and follistatin gene therapy.

### Is this medical advice?

No — this is a research and educational reference. FLGR242 is not an approved drug, and the pathway it is sold against is banned in sport.

---

Source: AmericanPeptide.com — https://americanpeptide.com/catalog/flgr242
Data license: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Attribution: AmericanPeptide.com.
Research reference only — computational and educational content, not medical advice.